• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Women’s Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Market - Product Image

Women’s Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Market

  • ID: 2011023
  • January 2012
  • 114 Pages
  • GBI Research

FEATURED COMPANIES

  • Eli-Lilly
  • Merck
  • Pfizer
  • Roche
  • Warner Chilcott
  • MORE

GBI Research, a leading business intelligence provider, has released its latest research “Women’s Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Market”. The report provides in-depth analysis of the drivers and barriers that affect the global Women’s Health market and analyzes the markets for women’s health disorders in the US, the top five markets in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, revenues and annual cost of therapy are forecast until 2017 for the key geographies, as well as for the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research finds that the women’s health therapeutics market will grow rapidly, largely due to the READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Eli-Lilly
  • Merck
  • Pfizer
  • Roche
  • Warner Chilcott
  • MORE

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Women’s Health Therapeutics Market to 2017 - Introduction
2.1 GBI Research Report Guidance

3 Women’s Health Therapeutics Market to 2017 - Market Overview
3.1 Introduction
3.2 Revenue Forecasts for Women’s Health Therapeutics Market
3.2.1 Revenues
3.2.2 Annual Cost of Therapy
3.2.3 Generic Share
3.3 Treatment Usage Patterns
3.4 Drivers and Barriers for Women’s Health Therapeutics Market
3.4.1 Drivers for Women’s Health Therapeutics Market
3.4.2 Barriers for Women’s Health Therapeutics Market

4 Women’s Health Therapeutics Market to 2017 - Geographical Landscape
4.1 The US
4.1.1 Revenue
4.1.2 Annual Cost of Therapy
4.1.3 Treatment Usage Pattern
4.2 Top Five Countries of Europe
4.2.1 Revenue
4.2.2 Annual Cost of Therapy
4.2.3 Treatment Usage Pattern
4.3 Japan
4.3.1 Revenue
4.3.2 Annual Cost of Therapy
4.3.3 Treatment Usage Pattern

5 Women’s Health Therapeutics Market to 2017 - Therapeutic Landscape
5.1 Menopause
5.1.1 Introduction
5.1.2 Revenues
5.1.3 Generic Share
5.1.4 Annual Cost of Therapy
5.1.5 Treatment Usage Patterns
5.1.6 Drivers and Barriers for Menopause
5.2 Post Menopausal Osteoporosis
5.2.1 Introduction
5.2.2 Revenues
5.2.3 Generic Share
5.2.4 Annual Cost of Therapy
5.2.5 Treatment Usage Patterns
5.2.6 Treatment Flow Algorithm
5.2.7 Drivers and Barriers for Post Menopausal Osteoporosis
5.3 Endometriosis
5.3.1 Introduction
5.3.2 Revenues
5.3.3 Generic Share
5.3.4 Annual Cost of Therapy
5.3.5 Treatment Usage Patterns
5.3.6 Treatment Flow Algorithm
5.3.7 Drivers and Barriers for Endometriosis
5.4 Urinary Incontinence
5.4.1 Introduction
5.4.2 Revenues
5.4.3 Generic Share
5.4.4 Annual Cost of Therapy
5.4.5 Treatment Usage Patterns
5.4.6 Treatment Flow Algorithm
5.4.7 Drivers and Barriers for Urinary Incontinence

6 Women’s Health Therapeutics Market to 2017 - Pipeline Analysis
6.1 Introduction
6.1.1 Research and Development Pipeline - Menopause
6.1.2 Research and Development Pipeline - Postmenopausal Osteoporosis
6.1.3 Research and Development Pipeline - Endometriosis
6.1.4 Research and Development Pipeline - Urinary Incontinence
6.2 Profiles of Promising Drugs in the Women’s Health Therapeutics Market
6.2.1 Aprela (Bazedoxifene/Conjugated Estrogen)
6.2.2 Pristiq (Desvenlaxafine, DVS-233)
6.2.3 Visanne
6.2.4 Elagolix (NBI-56418)
6.2.5 Odanacatib (MK-0822)
6.2.6 Viviant (Bazedoxifene)
6.2.7 YM178
6.2.8 GRC 6211

7 Women’s Health Therapeutics Market to 2017- Competitive Landscape
7.1 Market Share Analysis - Women’s Health Therapeutics Market
7.2 Major Marketed Products: Women’s Health Therapeutics Market
7.2.1 Detrol (tolterodine tartrate)
7.2.2 Premarin
7.2.3 Evista (raloxifene hydrochloride)
7.2.4 Actonel (Risedronate sodium)
7.3 Competitive Profiling
7.3.1 Pfizer
7.3.2 Eli-Lilly
7.3.3 Merck
7.3.4 Roche
7.3.5 Warner Chilcott

8 Women’s Health Therapeutics Market to 2017 - M&A Landscape
8.1 M&A Landscape
8.1.1 M&A Deals by Year
8.1.2 M&A Deals by Deal Type
8.1.3 M&A Deals by Geography
8.1.4 M&A Deals by Value
8.1.5 Top Five M&A Deals by Value
8.2 R&D Licensing Agreements
8.2.1 Deals by Year
8.2.2 Deals by Geography
8.2.3 Deals by Value ($)
8.3 Co-Development Agreements
8.3.1 Co-Development Agreements by Year
8.3.2 Co-Development Agreements by Geography
8.3.3 Co-Development Agreements by Value

9 Women’s Health Therapeutics Market to 2017 - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Section Wise Methodology
9.3.5 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources

1.1 List of Tables
Table 1: Women’s Health Therapeutics Market, Global, Revenue, ($m), 2002 - 2010
Table 2: Women’s Health Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017
Table 3: Women’s Health Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010
Table 4: Women’s Health Therapeutics Market, Global, Revenue by Geography, ($m), 2010 - 2017
Table 5: Women’s Health Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2010
Table 6: Women’s Health Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010 - 2017
Table 7: Women’s Health Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2010
Table 8: Women’s Health Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010 - 2017
Table 9: Women’s Health Therapeutics Market, The US, Revenue, ($m), 2002 - 2010
Table 10: Women’s Health Therapeutics Market, The US, Revenue Forecasts, ($m), 2010 - 2017
Table 11: Women’s Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2002 - 2010
Table 12: Women’s Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2010 - 2017
Table 13: Women’s Health Therapeutics Market, The US, Treatment Usage Patterns, (million), 2002 - 2010
Table 14: Women’s Health Therapeutics Market, The US, Treatment Usage Patterns, (million), 2010 - 2017
Table 15: Women’s Health Therapeutics Market, Top Five Countries of Europe, Revenue, ($m), 2002 - 2010
Table 16: Women’s Health Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, ($m), 2010 - 2017
Table 17: Women’s Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2002-2010
Table 18: Women’s Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2010 - 2017
Table 19: Women’s Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2002 - 2010
Table 20: Women’s Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2010 - 2017
Table 21: Women’s Health Therapeutics Market, Japan, Revenue, ($m), 2002 - 2010
Table 22: Women’s Health Therapeutics Market, Japan, Revenue Forecasts, ($m), 2010 - 2017
Table 23: Women’s Health Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2002 - 2010
Table 24: Women’s Health Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2010- 2017
Table 25: Women’s Health Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2002 - 2010
Table 26: Women’s Health Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2010 - 2017
Table 27: Menopause Therapeutics Market, Global, Revenue, ($m), 2002 - 2010
Table 28: Menopause Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017
Table 29: Menopause Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010
Table 30: Menopause Therapeutics Market, Global, Revenue by Geography, ($m), 2010 -2017
Table 31: Menopause Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2010
Table 32: Menopause Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010 - 2017
Table 33: Menopause Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2010
Table 34: Menopause Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010 - 2017
Table 35: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue, ($m), 2002 - 2010
Table 36: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017
Table 37: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010
Table 38: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue by Geography, ($m), 2010 - 2017
Table 39: Post Menopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2010
Table 40: Post Menopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010 - 2017
Table 41: Post Menopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2010
Table 42: Post Menopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010 - 2017
Table 43: Endometriosis Therapeutics Market, Global, Revenue, ($m), 2002 - 2010
Table 44: Endometriosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017
Table 45: Endometriosis Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010
Table 46: Endometriosis Therapeutics Market, Global, Revenue by Geography, ($m), 2010 - 2017
Table 47: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010
Table 48: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017
Table 49: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002 - 2010
Table 50: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2010 - 2017
Table 51: Urinary Incontinence Therapeutics Market, Global, Revenue, ($m), 2002 - 2010
Table 52: Urinary Incontinence Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017
Table 53: Urinary Incontinence Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010
Table 54: Urinary Incontinence Therapeutics Market, Global, Revenue by Geography, ($m), 2010 - 2017
Table 55: Urinary Incontinence Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2010
Table 56: Urinary Incontinence Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010 - 2017
Table 57: Urinary Incontinence Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2010
Table 58: Urinary Incontinence Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010 - 2017
Table 59: Women’s Health Therapeutics Market, Global, Pipeline by Phase, 2011
Table 60: Women’s Health Therapeutics Market, Global, Pipeline by Indication, 2011
Table 61: Menopause Therapeutics Market, Global, Pipeline, Pre-Clinical Stage Molecules, 2011
Table 62: Menopause Therapeutics Market, Global, Pipeline, IND Filed Stage Molecules, 2011
Table 63: Menopause Therapeutics Market, Global, Pipeline, Phase II Stage Molecules, 2011
Table 64: Menopause Therapeutics Market, Global, Pipeline, Phase III Stage Molecules, 2011
Table 65: Menopause Therapeutics Market, Global, Pipeline, NDA Filed Molecules, 2011
Table 66: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline, Phase I Stage Molecules, 2011
Table 67: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline, Phase II Stage Molecules, 2011
Table 68: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline, Phase III Stage Molecules, 2011
Table 69: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline, NDA Filed Molecules, 2011
Table 70: Endometriosis Therapeutics Market, Pipeline, Global, Pre-Clinical Stage Molecules, 2011
Table 71: Endometriosis Therapeutics Market, Global, Pipeline, Phase I Stage Molecules, 2011
Table 72: Endometriosis Therapeutics Market, Global, Pipeline, Phase II Stage Molecules, 2011
Table 73: Endometriosis Therapeutics Market, Global, Pipeline, Phase III Stage Molecules, 2011
Table 74: Urinary Incontinence Therapeutics Market, Global, Pipeline, Pre-Clinical Stage Molecules, 2011
Table 75: Urinary Incontinence Therapeutics Market, Global, Pipeline, Phase I Stage Molecules, 2011
Table 76: Urinary Incontinence Therapeutics Market, Global, Pipeline, Phase II Stage Molecules, 2011
Table 77: Urinary Incontinence Therapeutics Market, Global, Pipeline, Phase III Stage Molecules, 2011
Table 78: Urinary Incontinence Therapeutics Market, Global, Pipeline, NDA Filed Molecules, 2011
Table 79: Women’s Health Therapeutics Market, Marketed Drug Revenues, 2010
Table 80: Women’s Health Therapeutics Market, Global, M&A Deals by Type, 2004-2011
Table 81: Women’s Health Therapeutics Market, Global, M&A Deals by Geography, 2004-2011
Table 82: Women’s Health Therapeutics Market, Global, M&A Deals by Value, 2004-2011
Table 83: Women’s Health Therapeutics Market, Global, Top Five M&A Deals by Value, ($m), 2005-2010
Table 84: Women’s Health Therapeutics Market, Global, Licensing Agreements by Geography, 2004-2011
Table 85: Women’s Health Therapeutics Market, Global, Licensing Agreements by Value, ($m), 2004-2011
Table 86: Women’s Health Therapeutics Market, Global, Co-Development Agreements by Geography, 2004-2011
Table 87: Women’s Health Therapeutics Market, Global, Co-Development Agreements by Value, ($m), 2004-2011

1.2 List of Figures
Figure 1: Women’s Health Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017
Figure 2: Women’s Health Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017
Figure 3: Women’s Health Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2017
Figure 4: Women’s Health Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017
Figure 5: Women’s Health Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2017
Figure 6: Women’s Health Therapeutics Market, Global, Drivers and Barriers, 2010
Figure 7: Women’s Health Therapeutics Market, The US, Revenue Forecasts, ($m), 2002 - 2017
Figure 8: Women’s Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2002 - 2017
Figure 9: Women’s Health Therapeutics Market, The US, Treatment Usage Patterns, (million), 2002 - 2017
Figure 10: Women’s Health Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, ($m), 2002 - 2017
Figure 11: Women’s Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2002 - 2017
Figure 12: Women’s Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2002 - 2017
Figure 13: Women’s Health Therapeutics Market, Japan, Revenue Forecasts, ($m), 2002 - 2017
Figure 14: Women’s Health Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2002 - 2017
Figure 15: Women’s Health Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2002 - 2017
Figure 16: Menopause Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017
Figure 17: Menopause Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017
Figure 18: Menopause Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017
Figure 19: Menopause Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2017
Figure 20: Menopause Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2017
Figure 21: Menopause Therapeutics Market, Global, Drivers and Barriers, 2010
Figure 22: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017
Figure 23: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017
Figure 24: Post Menopausal Osteoporosis Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017
Figure 25: Post Menopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2017
Figure 26: Post Menopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2017
Figure 27: Post Menopausal Osteoporosis Therapeutics Market, Treatment Flow Algorithm, 2010
Figure 28: Post Menopausal Osteoporosis Therapeutics Market, Global, Drivers and Barriers, 2010
Figure 29: Endometriosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017
Figure 30: Endometriosis Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017
Figure 31: Endometriosis Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017
Figure 32: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017
Figure 33: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002 - 2017
Figure 34: Endometriosis Therapeutics Market, Treatment Flow Algorithm, 2010
Figure 35: Endometriosis Therapeutics Market, Global, Drivers and Barriers, 2010
Figure 36: Urinary Incontinence Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017
Figure 37: Urinary Incontinence Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017
Figure 38: Urinary Incontinence Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017
Figure 39: Urinary Incontinence Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2017
Figure 40: Urinary Incontinence Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2017
Figure 41: Women’s health Therapeutics to 2017, UI Treatment Algorithm Part-1
Figure 42: Women’s Health Therapeutics to 2017, UI Treatment Algorithm, Part-2
Figure 43: Urinary Incontinence Therapeutics Market, Global, Drivers and Barriers, 2010
Figure 44: Women’s Health Therapeutics Market, Global, Pipeline by Phase, (%), 2011
Figure 45: Women’s Health Therapeutics Market, Global, Pipeline by Indication (%), 2011
Figure 46: Women’s Health Therapeutics Market, Market Share Analysis, (%), 2010
Figure 47: Women’s Health Therapeutics Market, Pfizer SWOT Analysis, 2011
Figure 48: Women’s Health Therapeutics Market, Eli-Lilly SWOT Analysis, 2011
Figure 49: Women’s Health Therapeutics Market, Merck SWOT Analysis, 2011
Figure 50: Women’s Health Therapeutics Market, Roche SWOT Analysis, 2011
Figure 51: Women’s Health Therapeutics Market, Warner Chilcott SWOT Analysis, 2011
Figure 52: Women’s Health Therapeutics Market, Global, M&A Deals by Year, 2004-2011
Figure 53: Women’s Health Therapeutics Market, Global, M&A Deals by Type, (%), 2004-2011
Figure 54: Women’s Health Therapeutics Market, Global, M&A Deals by Geography, (%), 2004-2011
Figure 55: Women’s Health Therapeutics Market, Global, M&A Deals by Value, (%), 2004-2011
Figure 56: Women’s Health Therapeutics Market, Global, Licensing Agreements by Year, 2004-2011
Figure 57: Women’s Health Therapeutics Market, Global, Licensing Agreements by Geography, (%), 2004-2011
Figure 58: Women’s Health Therapeutics Market, Global, Licensing Agreements by Value, (%), 2004-2011
Figure 59: Women’s Health Therapeutics Market, Global, Co-Development Agreements by Year, 2004-2011
Figure 60: Women’s Health Therapeutics Market, Global, Co-Development Agreements by Geography, (%), 2004-2011
Figure 61: Women’s Health Therapeutics Market, Global, Co-Development Agreements by Value, (%), 2004-2011
Figure 62: GBI Research Market Forecasting Model

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Eli-Lilly
  • Merck
  • Pfizer
  • Roche
  • Warner Chilcott
  • MORE

GBI Research, a leading business intelligence provider, has released its latest research “Women’s Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Markets”. The report provides in-depth analysis of the drivers and barriers that affect the Women’s Health market and analyzes the markets for women’s health disorders in the US, the top five markets in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, revenues, annual cost of therapy and treatment flow algorithm are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. The report also includes insights into the respiratory disorders R&D product pipeline.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The Global Women’s Health Therapeutics Market is Forecast to Grow Rapidly from 2010 to 2017

In 2010, the global women’s health therapeutics market was estimated to be worth $14,530m, after a Compound Annual Growth Rate (CAGR) of 3.5% between 2002 and 2010. By 2017 the market is estimated to reach $24,671m, indicating a CAGR of 7.9% between 2010 and 2017. Owing to several factors such as the publication of the Women’s Health Initiative (WHI) study results, and a lack of effective therapeutics, the women’s health therapeutics market grew only moderately between 2002 and 2010. However, the launch of novel therapeutics in the near future is expected to satisfy the unmet need in the market. This will have a pronounced effect on positive growth in the menopause therapeutics market.

The current women’s health therapeutics pipeline is promising, with a strong line-up of first-in-class molecules in late stages of clinical development such as Pristiq (desvenlafaxine), Aprela (bazedoxifene/conjugated estrogens), Menerba (MF101) and Elagolix (NBI-56418). In addition, the recent launch of potential blockbuster drugs such as Prolia (denosumab) for the treatment of postmenopausal osteoporosis will offset the patent expirations of several major drugs, including Fosamax (alendronate sodium), Boniva (ibandronate sodium) and Actonel (risedronate sodium). The women’s health therapeutics market is an attractive market with huge opportunities for novel entrants with high safety and efficacy profiles.

Note: Product cover images may vary from those shown

- Pfizer
- Eli-Lilly
- Merck
- Roche
- Warner Chilcott

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos